Bio‐Engineered Fungal‐MOF Nanoplatform Synergizes Macrophage Polarization and Checkpoint Blockade for Potent Melanoma Immunotherapy
{"The":[0,67],"clinical":[1],"efficacy":[2],"of":[3,24,97],"melanoma":[4],"immunotherapy":[5,173],"is":[6,38],"frequently":[7],"compromised":[8],"by":[9,17],"an":[10,121,145],"immunosuppressive,":[11],"\\"cold\\"":[12],"tumor":[13,158],"microenvironment":[14,85],"(TME)":[15],"driven":[16],"redox":[18],"dysregulation":[19],"and":[20,54,78,93,155],"the":[21,82,87,107,111,128,142],"metabolic":[22,113],"polarization":[23],"tumor-associated":[25],"macrophages":[26],"(TAMs).":[27],"To":[28],"overcome":[29,172],"these":[30],"intertwined":[31],"barriers,":[32],"a":[33,43,51,55,61,95,167],"macrophage-targeted,":[34],"biomimetic":[35,68],"nanoplatform":[36],"(MOF-808-Ro-G/N)":[37],"developed.":[39],"This":[40],"system":[41],"integrates":[42],"catalytic":[44],"metal-organic":[45],"framework":[46],"(MOF-808)":[47],"core":[48,89],"loaded":[49],"with":[50],"PERK":[52],"inhibitor":[53],"CD47":[56],"blocking":[57,127],"agent,":[58],"encapsulated":[59],"within":[60],"Rhizopus":[62],"oryzae":[63],"(Ro)-derived":[64],"fungal":[65],"shell.":[66],"shell":[69],"leverages":[70],"Dectin-1":[71],"interactions":[72],"to":[73,90,131,171],"enable":[74],"precise":[75],"TAM":[76],"targeting":[77],"accumulation.":[79],"Upon":[80],"endocytosis,":[81],"acidic":[83],"endosomal":[84],"activates":[86],"MOF":[88],"deplete":[91],"glutathione":[92],"trigger":[94],"surge":[96],"reactive":[98],"oxygen":[99],"species,":[100],"thereby":[101],"inducing":[102],"immunogenic":[103],"cell":[104],"death.":[105],"Synergistically,":[106],"released":[108],"payloads":[109],"disrupt":[110],"PERK-ATF4":[112],"stress":[114],"axis,":[115],"reprogramming":[116],"pro-tumorigenic":[117],"M2":[118],"TAMs":[119],"toward":[120],"anti-tumor":[122],"M1":[123],"phenotype,":[124],"while":[125],"concurrently":[126],"CD47-SIRPα":[129],"checkpoint":[130],"restore":[132],"macrophage":[133],"phagocytosis.":[134],"Through":[135],"this":[136,162],"orchestrated":[137],"modulation,":[138],"MOF-808-Ro-G/N":[139],"effectively":[140],"remodels":[141],"TME":[143],"into":[144],"immunologically":[146],"\\"hot\\"":[147],"niche,":[148],"promoting":[149],"robust":[150],"cytotoxic":[151],"T":[152],"lymphocyte":[153],"infiltration":[154],"achieving":[156],"substantial":[157],"growth":[159],"suppression.":[160],"Overall,":[161],"\\"metabolic-immune":[163],"dual-reprogramming\\"":[164],"strategy":[165],"provides":[166],"promising":[168],"materials-driven":[169],"paradigm":[170],"resistance":[174],"in":[175],"solid":[176],"tumors.":[177]}
Authors
- Jueshuo Guo
- Yaping Mai
- Wenbao Zuo (ORCID: https://orcid.org/0009-0001-7066-1838)
- Jianhong Yang (ORCID: https://orcid.org/0000-0002-5838-3257)
- Tingting Meng
- Na Yu
- Xiaolong Li
Institutions
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
Publication Details
- Journal
- Advanced Healthcare Materials
- Published
- 2026-08-26
- DOI
- https://doi.org/10.1002/adhm.71650
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00